Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Gains from Investment Securities (2021 - 2025)

ARS Pharmaceuticals' Gains from Investment Securities history spans 5 years, with the latest figure at $8.3 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 8400.0% year-over-year to $8.3 million; the TTM value through Dec 2025 reached $5.2 million, up 316.67%, while the annual FY2025 figure was $9.1 million, 39.98% down from the prior year.
  • Gains from Investment Securities for Q4 2025 was $8.3 million at ARS Pharmaceuticals, up from $300000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $17.3 million in Q1 2025 and bottomed at -$5.7 million in Q3 2023.
  • The 5-year median for Gains from Investment Securities is $1.1 million (2022), against an average of $3.4 million.
  • The largest YoY upside for Gains from Investment Securities was 769270.9% in 2023 against a maximum downside of 573.82% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at $4.8 million in 2021, then tumbled by 121.95% to -$1.1 million in 2022, then soared by 1184.29% to $11.5 million in 2023, then tumbled by 100.87% to -$100000.0 in 2024, then surged by 8400.0% to $8.3 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Gains from Investment Securities are $8.3 million (Q4 2025), $300000.0 (Q2 2025), and $17.3 million (Q1 2025).